Dlin-MC3-DMA: Ionizable Cationic Liposome for Advanced mRNA and siRNA Delivery

Executive Summary: Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7) is an ionizable cationic liposome lipid essential for potent siRNA and mRNA delivery via lipid nanoparticles (LNPs) (APExBIO). It is positively charged at acidic pH, promoting endosomal escape and cytoplasmic release of nucleic acids, and neutral at physiological pH, reducing off-target toxicity (Rafiei et al., 2025). Dlin-MC3-DMA shows approximately 1000-fold greater potency for hepatic gene silencing than its precursor DLin-DMA, with ED₅₀ values as low as 0.005 mg/kg in mice. It is a critical material for machine learning-optimized LNPs in immunomodulatory and cancer immunochemotherapy (see related analysis). Dlin-MC3-DMA enables reproducible, high-efficiency mRNA vaccine formulation and nucleic acid delivery in translational research.

Biological Rationale

Dlin-MC3-DMA belongs to the class of ionizable cationic lipids, which are foundational in the design of lipid nanoparticles for nucleic acid delivery (Rafiei et al., 2025). The biological rationale for using ionizable cationic liposomes centers on their unique pH-sensitive charge behavior. At physiological pH (~7.4), Dlin-MC3-DMA is largely neutral, minimizing nonspecific protein binding and blood toxicity. However, within the acidic endosomal compartment (pH 5.0–6.0), it becomes protonated, facilitating membrane fusion and endosomal escape. This duality enables precise cytoplasmic delivery of siRNA or mRNA payloads while sparing healthy tissues from excess exposure (see mechanistic review). This mechanism is especially critical for hepatic gene silencing and emerging immunomodulatory therapies targeting microglia and tumor cells.

Mechanism of Action of Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7)

Dlin-MC3-DMA’s action is governed by its ionizable tertiary amine, enabling pH-dependent charge switching (Rafiei et al., 2025). In LNPs, it is typically co-formulated with DSPC, cholesterol, and PEGylated lipids (e.g., PEG-DMG). At acidic pH, the lipid becomes cationic, enhancing electrostatic interactions with anionic endosomal membranes. This promotes membrane fusion, destabilization, and subsequent release of siRNA or mRNA into the cytosol (for molecular modeling details). At neutral pH, the reduced charge helps avoid aggregation and minimizes systemic toxicity. The efficiency of this endosomal escape mechanism is a principal determinant of gene silencing and protein expression outcomes in vivo.

Evidence & Benchmarks

• Dlin-MC3-DMA enables LNPs to silence hepatic genes at doses as low as 0.005 mg/kg in mice, achieving ~1000-fold higher potency than DLin-DMA (Rafiei et al., 2025, DOI).
• In non-human primates, the ED₅₀ for transthyretin (TTR) gene silencing is 0.03 mg/kg, with no major off-target toxicity reported at effective doses (Rafiei et al., 2025, DOI).
• Machine learning-guided LNPs incorporating Dlin-MC3-DMA efficiently delivered mRNA to LPS-activated BV2 murine microglia, suppressing inflammatory phenotypes and increasing IL10 expression (Rafiei et al., 2025, DOI).
• Dlin-MC3-DMA-based LNPs facilitate robust endosomal escape, as evidenced by cytoplasmic mRNA expression in both murine and human iPSC-derived microglia (Rafiei et al., 2025, DOI).
• The lipid is insoluble in water and DMSO, but soluble in ethanol at ≥152.6 mg/mL, supporting scalable formulation (APExBIO product data).

Applications, Limits & Misconceptions

Dlin-MC3-DMA is validated for multiple applications in nucleic acid therapeutics. These include:

• Lipid nanoparticle siRNA delivery for hepatic gene silencing and rare genetic disorders.
• mRNA drug delivery lipid for vaccines, protein replacement, and immunomodulation, with proven efficacy in preclinical neuroinflammatory and cancer models (see immunomodulation update).
• Cancer immunochemotherapy via targeted delivery of immunostimulatory mRNA or siRNA.
• Lipid nanoparticle-mediated gene silencing platforms for translational and machine learning-optimized approaches.

Common Pitfalls or Misconceptions

• Not water-soluble: Dlin-MC3-DMA must be dissolved in ethanol; use in aqueous buffers leads to aggregation and formulation failure.
• Not suitable for DNA delivery: Optimized for mRNA and siRNA; performance with plasmid DNA is markedly lower due to size and charge differences.
• pH sensitivity: Efficacy depends on endosomal acidification; agents that raise endosomal pH diminish activity.
• In vivo toxicity at supra-physiological doses: Although neutral at pH 7.4, very high doses or improper formulation can still cause off-target effects.
• Not a standalone immunomodulator: Activity is carrier-dependent; Dlin-MC3-DMA does not directly activate immune pathways absent a nucleic acid cargo.

This article clarifies and expands upon the mechanistic focus of Dlin-MC3-DMA: Mechanistic Mastery and Strategic Acceleration by directly benchmarking machine learning-assisted LNP optimization and integrating quantitative potency data.

Workflow Integration & Parameters

For experimental use, Dlin-MC3-DMA is supplied by APExBIO (SKU: A8791). It should be stored at −20°C or lower; ethanol solutions must be prepared fresh and used promptly to ensure chemical integrity (APExBIO). Standard LNP formulation ratios in preclinical studies are typically: Dlin-MC3-DMA:DSPC:cholesterol:PEG-lipid at 50:10:38.5:1.5 mol%. LNPs are assembled via rapid ethanol injection or microfluidic mixing. Nucleic acid payloads (siRNA or mRNA) are mixed at N/P ratios (nitrogen in lipid/phosphate in nucleic acid) of 3–6, depending on application (for workflow detail). Buffer exchange into isotonic solution is mandatory before in vivo use.

Conclusion & Outlook

Dlin-MC3-DMA is a gold-standard ionizable cationic liposome for high-efficiency lipid nanoparticle siRNA and mRNA delivery. Its unique pH-responsiveness and benchmarked in vivo performance underpin its widespread adoption in mRNA vaccines, gene silencing, and immunochemotherapy. Ongoing advances in machine learning-guided LNP optimization and immunomodulatory formulations are expected to further expand its applications beyond hepatic targets, including neuroinflammation and tumor immunotherapy (Rafiei et al., 2025). APExBIO remains a primary source for research-grade Dlin-MC3-DMA (A8791) for translational and preclinical workflows.